Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life. Sodium-glucose co-transporter 2 inhibitor (SGLT2i) is a new type of hypoglycemic drug, which can regulate blood glucose level safely and effective...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_6c5bc8943b874080b0118e68b3c55c07 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Yuling Jing |e author |
| 700 | 1 | 0 | |a Ruixue Yang |e author |
| 700 | 1 | 0 | |a Wen Chen |e author |
| 700 | 1 | 0 | |a Qiang Ye |e author |
| 245 | 0 | 0 | |a Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors |
| 260 | |b Frontiers Media S.A., |c 2022-06-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2022.898718 | ||
| 520 | |a Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life. Sodium-glucose co-transporter 2 inhibitor (SGLT2i) is a new type of hypoglycemic drug, which can regulate blood glucose level safely and effectively. Additionally, it reduces the occurrence and progression of heart failure and cardiovascular events significantly. Recently, studies have found that SGLT2i can alleviate the occurrence and progression of cardiac arrhythmias; however, the exact mechanism remains unclear. In this review, we aimed to discuss and summarize new literature on different modes in which SGLT2i ameliorates the occurrence and development of cardiac arrhythmias. | ||
| 546 | |a EN | ||
| 690 | |a arrhythmia | ||
| 690 | |a SGLT2I | ||
| 690 | |a cardiac electrical remodeling | ||
| 690 | |a mitochondrial dysfunction | ||
| 690 | |a oxidative stress | ||
| 690 | |a cardiac structural remodeling | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 13 (2022) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2022.898718/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/6c5bc8943b874080b0118e68b3c55c07 |z Connect to this object online. |